Table 2. Patient Outcomes.
| Baseline | 12 months after surgery | Mean improvement in score (%) | |||||
|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | p value | |
| UPDRS III (off)* | 41.55±13.90 | 41.97±12.98 | 28.00±12.16 | 31.27±13.96 | 29.19±27.40 | 22.32±33.45 | 0.276 |
| UPDRS III (on)* | 19.64±9.51 | 16.67±9.01 | 18.01±9.11 | 18.85±11.28 | 8.95±39.95 | -5.12±47.59 | 0.123 |
| UPDRS IV* | 8.13±4.41 | 6.97±3.85 | 5.79±3.36 | 4.85±3.82 | 23.25±42.97 | 23.17±48.79 | 0.993 |
| Dyskinesia subscore* | 4.30±2.43 | 4.33±2.78 | 1.87±2.52 | 1.85±2.31 | 61.90±42.67 | 57.14±49.17 | 0.619 |
| LEDD* | 1120.54±460.76 | 746.74±407.01 | 402.31±284.04 | 828.48±368.41 | 62.31±22.59 | -23.08±52.41 | 0.000 |
UPDRS, Unified Parkinson's Disease Rating Scale; LEDD, levodopa equivalent daily dose.
*Presented as mean±standard deviation.